Deans' stroke musings: Inhibition of microRNA-126-3p attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, October 22, 2025

Inhibition of microRNA-126-3p attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway

Didn't your competent? doctor do something for your recovery with microRNA years ago? NO? NO followup human testing? NOTHING? FIRE YOUR DOCTOR!

microRNA (43 posts to May 2012)

Inhibition of microRNA-126-3p attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway

https://doi.org/10.1016/j.jneuroim.2025.578772 Get rights and content

Highlights

•
miR-126 regulates LRP6 in the Wnt/β-catenin pathway post-stroke.
•
Inhibition of miR-126 reduces ischemic brain injury in mice.
•
Increased miR-126 levels enhance neuronal apoptosis after MCAO.
•
LRP6 activation restores Wnt/β-catenin signaling and improves outcomes.
•
Targeting miR-126 presents a potential therapeutic strategy for stroke.

Abstract

MicroRNA-126 (miR-126) has emerged as a potential key regulator in ischemic stroke. Yet, its exact mechanism of action is still unexplored. This study aims to investigate whether miR-126 targets and regulates the low-density lipoprotein receptor-related protein (LRP6), an important co-receptor in the Wnt/β-catenin signaling pathway, to reduce ischemic brain injury in mice. C57BL/6 J mice were randomly divided into Sham group, Middle Cerebral Artery Occlusion (MCAO) group, MCAO+miR-126 antagomir group, MCAO+ antagomir NC group, MCAO+miR-126 agomir group and MCAO + agomir NC group. The Garcia nervous system score assessed the neurobehavior of the mice. Infarct volume was determined by 2,3,5-triphenyl tetrazolium chloride (TTC) staining, and the extent of cerebral ischemia-reperfusion injury was assessed by Nissl staining. The miR-126 level was detected by real-time PCR, and the apoptosis index was detected by Western blot. A luciferase reporter assay was applied to demonstrate that LRP6 is the target protein of miR-126. The increased expression of miR-126 in MCAO mice inhibits the Wnt/LRP6/β-catenin pathway and enhances neuronal apoptosis. Inhibition of miR-126 alleviates the infarct area, motor ability damage, and apoptosis in MCAO mice. Additionally, Western blot results and luciferase reporter assay showed that inhibition of miR-126 activates the Wnt/β-catenin signaling pathway via LRP6. Our data suggest that inhibition of microRNA-126 attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway.